Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: European J Org Chem. 2015 Aug 14;2015(27):5919–5924. doi: 10.1002/ejoc.201500986

A Mild and General One-Pot Synthesis of Densely Functionalized Diaryliodonium Salts

Linlin Qin [a],, Bao Hu [a],[b],, Kiel D Neumann [a], Ethan J Linstad [a], Katelyenn McCauley [a], Jordan Veness [a], Jayson J Kempinger [a], Stephen G DiMagno [a],
PMCID: PMC4824678  NIHMSID: NIHMS749051  PMID: 27065751

Abstract

Diaryliodonium salts are powerful and widely used arylating agents in organic chemistry. Here we report a scalable, synthesis of densely functionalized diaryliodonium salts from aryl iodides under mild conditions. This two-step, one-pot process has remarkable functional group tolerance, is compatible with commonly employed acid-labile protective group strategies, avoids heavy metal and transition metal reagents, and provides a direct route to stable precursors to PET imaging agents.

Keywords: iodane synthesis, oxidation, diaryliodonium salts, Selectfluor, aryl iodides


Although diaryliodonium salts (diaryl-λ3-iodanes) were discovered more than a century ago,[1] their study is undergoing a renaissance in organic chemistry, where they serve as powerful, and widely applicable, arylation reagents.[25] These compounds arylate a multitude of organic and inorganic nucleophiles to provide functionalized arenes in excellent yields. In particular, the use of diaryliodonium salts as precursors to radiopharmaceuticals is an area of increasingly active research;[6] Sanford and Scott,[7] Pike,[8] Coenen,[9] DiMagno,[10] and other groups[11] have all demonstrated successful conversion of diaryliodonium salt precursors into 18F-labeled compounds for PET imaging.

Regiospecific methods to synthesize unsymmetrical diaryliodonium salts generally proceed through ArI(III) intermediates, which are generated either by oxidation of an aryl iodide or by addition of an I(III) electrophile to an aromatic compound. The second step involves coupling the electrophilic ArIX2 reagent with a second aryl moiety, either by ligand exchange with an aryl organometallic nucleophile (Ar-B(OH)2, ArSnR3, ArSiMe3, ArZnCl, ArBF3K), or by electrophilic aromatic substitution of an electron-rich arene.[2a,12] One-pot oxidation and ligand exchange reactions to synthesize diaryliodonium salts directly from arenes and iodoarenes have also been reported.[13] These approaches have been reviewed in detail by Merritt and Olofsson (Scheme 1).[2b] Preparation of the ArIX2 electrophile typically involves an oxidation under acidic conditions.

Scheme 1.

Scheme 1

Synthetic strategies for preparing diaryliodonium salts.[2b]

Driven by our interest in synthesizing radiofluorinated agents for positron emission tomography (PET) imaging,[10] we sought a general, one-pot method for preparing diverse diaryliodonium salts directly from the protected parent pharmaceuticals. Important parameters that need to be satisfied for the synthesis of radiopharmaceutical precursors are 1) functional group tolerance, 2) compatibility with commonly employed acid-labile protective group strategies, 3) the avoidance, at every step of the synthesis, of heavy metal reagents that could impact long term stability of the diaryliodonium salts or react with trace 18F-fluoride during labeling procedures, and 4) scalability. These restrictions are actually quite onerous, as is illustrated in Scheme 2 for the retrosynthesis of an unsymmetrical diaryliodonium salt derived from phenylalanine. Path A dictates an extremely mild oxidation process to satisfy restrictions 1 and 2, while path B requires generation an organometallic reagent under weakly basic conditions, and without the assistance of transition metal catalysis, to satisfy restrictions 1 and 3. While multistep workarounds for each of these restrictions may be possible, a direct route involving in situ oxidation of the suitably protected 4-iodophenylalanine followed by treatment with an organometallic reagent is clearly preferred.

Scheme 2.

Scheme 2

Retrosynthesis of an unsymmetrical diaryliodonium salt derived from phenylalanine.

In 2005, Shreeve[14] and coworkers reported that iodoarenes could be oxidized smoothly under neutral conditions with 2 eq. of Selectfluor (F-TEDA-2BF4, Scheme 3), but that the ArIF2 products formed proved to be too unstable to isolate in good yield. Importantly, they noted that yields of isolated ArI(III) species could be increased significantly in carboxylic acid solvents. Kita[15] and Ishihara[16] have also reported preparations of ArI(III) reagents with F-TEDA-2BF4 under acidic conditions. Guided by these promising results, we reinvestigated the F-TEDA-2BF4 oxidation of aryl iodides with the aim of developing a protic-acid-free route to stable, yet reactive ArI(III) electrophiles. Our strategy to achieve this goal was simply to replace the proton in acetic or trifluoroacetic acid with a fluorophilic Lewis acid. These efforts led to a direct, one-pot synthesis of unsymmetrical diaryliodonium salts that is centered on oxidation of the “valuable,” densely-functionalized aryl ligand.

Scheme 3.

Scheme 3

Preparation of ArI(III) reagents with F-TEDA-2BF4 from iodoarenes.

Surprisingly, treatment of 4-methoxyiodobenzene 1a with a mixture of F-TEDA-2BF4 (1.3 eq.) and trimethylsilyl acetate (TMSOAc, 2.6 eq.) in CD3CN provided stable 4-methoxyphenyliodonium diacetate 2a in almost quantitative yield, along with 2 full equivalents of trimethylsilyl fluoride (TMSF). In contrast, when the oxidation was performed under identical conditions, except that the hexafluorophosphate salt of Selectfluor (F-TEDA-2PF6) was employed, an unstable oxidation product formed, which gradually decomposed. In addition, an excess of TMSOAc remained at the end of the reaction. The resemblance of the TEDA-2PF6 oxidation to Shreeve’s “acid-free” F-TEDA-2BF4/CH3CN oxidation was striking; these data suggested that the tetrafluoroborate counterion (BF4) played a key role in stabilizing the oxidation product by serving as a source of fluoride (Scheme 4).

Scheme 4.

Scheme 4

A proposed mechanism for the oxidative diacetoxylation of iodoarenes in the presence of F-TEDA-2BF4 and TMSOAc.

Support for the proposed mechanism is found in the appearance of new signals, derived from multiple fluoroborate species, in the 19F NMR spectrum of the reaction mixture, and from multiple signals arising from coordinated diazabicyclo[2.2.2]octane in the 1H NMR spectrum. Addition of tetrabutylammonium terafluoroborate (TBABF4) to oxidations performed with F-TEDA-2PF6 proceeded in excellent yields with generation of the full 2 equivalents of TMSF, providing support for the critical role of BF4 in facilitating formation of 2a. The proposed mechanism is also consistent with the lower fluoride affinity of BF3 (pF = 8.31) compared to PF5 (pF = 9.49)[17], and suggests that the fluoride affinity of cationic ArIF derivatives is on a par with boron trifluoride, and may be reversible. Additional control experiments in which TMSOAc was combined with F-TEDA-2BF4, with TBABF4, or even TBABF4 in combination with 4-methoxyphenyliodonium diacetate did not generate any TMSF; these results are consistent with a cationic ArIF species acting as the fluoride transfer agent.

A brief survey of the oxidation conditions (Table 1) showed that a variety of electron-rich and electron-poor arenes could be oxidized smoothly to (diacetoxyiodo)arenes, 2, at or near room temperature; the electron-poor arenes required slightly more aggressive conditions to complete the oxidation. Reactions performed in CD3CN and monitored by 1H NMR spectroscopy indicated that the oxidation proceeded in excellent yield (>90%) in all cases; some losses were associated with the subsequent isolation of the ArI(OAc)2 products. Importantly, the straightforward preparation of 2g (Scheme 5) shows that the oxidation occurs under effectively neutral conditions; BOC protecting groups are not cleaved during this process.

Table 1.

Preparation of (diacetoxyiodo)arenes 2 from iodoarenes 1.[a]

graphic file with name nihms749051u1.jpg
Entry ArI R T [°C] t [h] Prod. Yield [%][b]
1 1a 4-OMe 23 3 2a 70
2 1b 2-OMe 23 3 2b 65
3 1c 3-CF3 23 8 2c 80
4 1d 3-CN 23 8 2d 70
5 1e 3,5-CO2Me 50 22 2e 93
6 1f 4-NO2 50 33 2f 85
[a]

Reaction conditions: 0.50 mmol scale, 6.0 mL of CH3CN, N2. For details of operations, see Supporting Information.

[b]

Isolated yields.

Scheme 5.

Scheme 5

Synthesis of (diacetoxyiodo)arene 2g from iodoarene 1g.

The losses associated with purification and isolation of (diacetoxyiodo)arenes made a direct, one-pot diaryliodonium salt synthesis an attractive goal. Potassium (4-methoxyphenyl)trifluoroborate, AnBF3K, was selected as the nucleophilic coupling partner because 1) anisole has been shown to be an excellent “dummy” directing group for a variety of arylation reactions, and 2) aryl transfer to any trifluoroborane generated during the oxidation step would regenerate the reagent.

Initial NMR-tube scale reactions (dry CD3CN, iodoarenes 1a1hh) indicated that efficient Selectfluor oxidation of diverse iodoarenes in the presence of TMSOAc was efficient (> 80% yield) and relatively rapid (2 – 48 h) at or near room temperature (See Supporting Information). Upon completion of the oxidation, AnBF3K, which resulted in no observable reaction; the reaction mixtures were treated with one equivalent of (diacetoxyiodo)arenes are insufficiently electrophilic to engage this aryl nucleophile. Formation of the diaryliodonium salt commenced immediately after the addition of a CD3CN solution of either trimethylsilyl trifluoroacetate (TMSTFA) or trimethylsilyl triflate (TMSOTf), and was complete within 10 minutes at room temperature. (As we have shown previously, a ligand exchange reaction between iodine and silicon [ArI(OAc)2 + TMSX ↔ ArI(OAc)(X) + TMSOAc] creates a Lewis acid buffer system that can be used to tune the electrophilicity of the I(III) center over a significant range.)[18] Iodine arylation with AnBF3K proceeded in excellent yield (> 95%) in all cases.

To demonstrate the practicality of the method, we prepared a relatively large number of unsymmetrical diaryliodonium triflates and hexafluorophosphates (Scheme 6). These compounds, which were selected largely for their potential use as radiosynthesis precursors, featured acid-sensitive (3(g, h, I, n, t, u, v, aa–ff) and base-sensitive (3(t–y, aa–ee) functionality. The larger scale reactions followed the procedure described above for the NMR tube reactions, except that an aqueous work-up, ion-exchange, and recrystallization of the products were performed (see Supporting Information). Significant losses were incurred during the isolation and recrystallization of some of the products, but even quite densely functionalized compounds could be prepared successfully on a multigram scale.

Scheme 6.

Scheme 6

Diaryliodonium salts prepared using the reported method.

Although most of the reactions reported in Scheme 6 were performed using glove box techniques, the use of rigorously anhydrous conditions and highly purified reagents and solvents are not required. For example, 3t was synthesized on the benchtop under nitrogen using as received reagents, and the yields were comparable to those obtained under rigorously dry conditions. In fact, the method is robust enough to be transferred to pilot plant facilities; as an example, a cGMP synthesis of a 100 gram lot of 3v, a diaryliodonium salt precursor to 18F-6-fluoro-L-DOPA[10a,10b] was recently completed[19] by a commercial concern. The reason this system tolerates the presence of adventitious moisture is that the oxidation generates its own acetate buffer if water is present during the course of the reaction. If extremely acid-sensitive functional groups are present in the molecule, additional leeway for the generation of Brønsted acids from water can be gained by adding N-chloromethyldiazabicyclo[2.2.2]octane tetrafluoroborate (CH2Cl-DABCO) at the beginning of the reaction. This compound, which is also generated in situ during the initial oxidation reaction, is a mild and non-reducing tertiary amine base that can scavenge small amounts of protic acid side products, if desired.

The scalable, heavy-metal-free, one-pot, two step synthesis of diaryliodonium salts described here has a remarkable functional group tolerance, and is compatible with commonly employed acid-labile protective group strategies. Unsymmetrical diaryliodonium salts possessing quite reactive functionalities, including succinimidyl esters and maleimides typically used for bioconjugation, may be synthesized with relative ease from their parent aryl iodides. This improved capability should streamline the development of diaryliodonium salts from complex, pharmaceutically relevant aromatic compounds and expand the scope of potential arylation reagents available for organic synthesis. Moreover, given the increasing importance of diaryliodonium salts as precursors to 18F-fluorinated radiopharmaceuticals, this simple methodology provides a direct route to stable precursors to PET imaging agents.

Experimental Section

Typical procedure for the benchtop, one-pot synthesis of a diaryliodonium salt 3t: Under an atmosphere of dry nitrogen, methyl (S)-2-(di-(tert-butoxycarbonyl)amino)-3-(4-iodophenyl)propanoate (3.0 mmol, 1.52 g, 1.0 eq.), SelectfluorTM (3.9 mmol, 1.39 g, 1.3 eq.) and 15 mL of dry CH3CN were introduced to an oven-dried Schlenk flask. A solution of TMSOAc (7.8 mmol, 1.03 g, 2.6 eq.) in dry CH3CN (5 mL) was added by syringe dropwise with stirring. This colorless mixture was stirred at room temperature for 24 h; a 1H NMR spectrum obtained from a withdrawn aliquot confirmed that the oxidation had reached >90% at this time. Solid potassium (4-methoxyphenyl)trifluoroborate (0.64 g, 3.0 mmol, 1.0 equiv.) was added directly to the flask against a flow of nitrogen. Once the added solid was dissolved and a homogeneous mixture was obtained (3 minutes), a solution of TMSOTf (0.67 g, 2.7 mmol, 0.9 eq.) in 10.0 mL of dry CH3CN was added dropwise by syringe and the yellowish mixture was allowed to stir at room temperature for 10 min. The solvents were removed under reduced pressure and 100 mL of 0.1 M acetate buffer (pH = 5) was added. The mixture was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers were added to a separatory funnel and washed with water (50 mL), and the wash water was extracted further (2 × 50 mL) with CH2Cl2. The combined organic extracts were dried over sodium sulfate, filtered, and the solvent was removed by rotary evaporation. The residue was placed under dynamic vacuum to obtain a yellow-tinged foam. This solid was dissolved in 10.0 mL ethyl acetate and added dropwise to a mixture of MTBE and hexane (1:4) to precipitate the diaryliodonium triflate product. The obtained solid was dissolved in 1 mL acetonitrile/water (9: 1 by volume) solution and passed down an Amberlite IRA-400 ion exchange column (triflate counterion). After removal of the solvents under reduced pressure, the purified iodonium triflate product (1.89 g, 83%) of was obtained as a colorless solid. 1H NMR (CD3CN, 400 MHz): δ 8.02 (d, J = 9.1 Hz, 2 H), 7.96 (d, J = 8.4 Hz, 2 H), 7.33 (d, J = 8.4 Hz, 2 H), 7.05 (d, J = 9.1 Hz, 2 H), 5.16 (dd, J1 = 10.9 Hz, J2 = 4.8 Hz, 1 H), 3.84 (s 3 H), 3.70 (s, 3 H), 3.43 (dd, J1 = 14.0 Hz, J2 = 4.8 Hz, 1 H), 3.21 (dd, J1 = 14.0 Hz, J2 = 10.9 Hz, 1 H), 1.27 (s, 18 H); 13C NMR (CD3CN, 176 MHz) δ 170.2, 163.4, 151.6, 143.7, 137.8, 134.9, 133.6, 122.0, 120.2, 118.2, 111.6, 101.5, 83.1, 58.6, 55.8, 52.1, 35.3, 27.0; 19F NMR (CD3CN, 376 MHz): δ −79.3 (s, 3 F); HRMS: (ESI) calcd. for C 27H 35INO7 [M–OTf]+ 612.1458; found: 612.1453.

Supplementary Material

supporting information

Acknowledgments

Research reported in this publication was supported by Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under award number R01 EB015536. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Bao Hu also thanks the National Natural Science Foundation of China (No. 21202148) for support.

Footnotes

Disclosures

The chemistry reported here is the subject of patent applications (PCT/US 2013/066830, WO 2014/066772) which have been licensed to Ground Fluor Pharmaceuticals, Inc., of Lincoln, NE (GFP). SGD and KDN are shareholders in GFP.

Supporting information for this article is given via a link at the end of the document.

References

  • 1.Hartmann C, Meyer V. Ber. 1894;27:502. [Google Scholar]
  • 2.Reviews: Bellina F, Rossi R. Tetrahedron. 2009;65:10269.Merritt EA, Olofsson B. Angew Chem Int Ed. 2009;48:9052. doi: 10.1002/anie.200904689.Yusubov MS, Maskaev AV, Zhdankin VV. ARKIVOC. 2011;(i):370.Rousseaux S, Vrancken E, Campagne JM. Angew Chem, Int Ed. 2012;51:10934. doi: 10.1002/anie.201205805.Grushin VV. Chem Soc Rev. 2000;29:315.Deprez Nicholas R, Sanford Melanie S. Inorg Chem. 2007;46:1924. doi: 10.1021/ic0620337.
  • 3.Selected recent tandem arylation of diaryliodonium salts, see: Chen J, Chen C, Chen J, Gao H, Qu H. Synlett. 2014;25:2721.Li J, Wang H, Sun J, Yang Y, Liu L. Org Biomol Chem. 2014;12:7904. doi: 10.1039/c4ob01504e.Li P, Cheng G, Zhang H, Xu X, Gao J, Cui X. J Org Chem. 2014;79:8156. doi: 10.1021/jo501334u.Li X, Xu J, Zhang P, Gao Y, Wu J, Tang G, Zhao Y. Synlett. 2014;25:2009.Liu F, Yang H, Hu X, Jiang G. Org Lett. 2014;16:6408. doi: 10.1021/ol503224u.Pang X, Chen C, Su X, Li M, Wen L. Org Lett. 2014;16:6228. doi: 10.1021/ol503156g.Guo W, Li S, Tang L, Li M, Wen L, Chen C. Org Lett. 2015;17:1232. doi: 10.1021/acs.orglett.5b00197.Modha SG, Greaney MF. J Am Chem Soc. 2015;137:1416. doi: 10.1021/ja5124754.Pang X, Lou Z, Li M, Wen L, Chen C. Eur J Org Chem. 2015:3361.Yang Y, Han J, Wu X, Xu S, Wang L. Tetrahedron Lett. 2015;56:3809.
  • 4.Selected recent examples of transition-metal-catalyzed arylation of diaryliodonium salts, see: Malmgren J, Nagendiran A, Tai CW, Baeckvall JE, Olofsson B. Chem Eur J. 2014;20:13531. doi: 10.1002/chem.201404017.Prakash M, Muthusamy S, Kesavan V. J Org Chem. 2014;79:7836. doi: 10.1021/jo501162s.Bhattarai B, Tay JH, Nagorny P. Chem Commun. 2015;51:5398. doi: 10.1039/c4cc08604j.Margraf N, Manolikakes G. J Org Chem. 2015;80:2582. doi: 10.1021/jo5027518.Chen J, Chen C, Chen J, Wang G, Qu H. Chem Commun. 2015;51:1356. doi: 10.1039/c4cc08363f.Moon SY, Koh M, Rathwell K, Jung SH, Kim WS. Tetrahedron. 2015;71:1566.Iyanaga M, Aihara Y, Chatani N. J Org Chem. 2014;79:11933. doi: 10.1021/jo501691f.Cahard E, Male HPJ, Tissot M, Gaunt MJ. J Am Chem Soc. 2015;137:7986. doi: 10.1021/jacs.5b03937.
  • 5.Selected recent examples of transition-metal-free arylation of diaryliodonium salts, see: Castro LCM, Chatani N. Synthesis. 2014;46:2312.Senaweera SM, Weaver JD. J Org Chem. 2014;79:10466. doi: 10.1021/jo502075p.Thorat PB, Waghmode NA, Karade NN. Tetrahedron Lett. 2014;55:5718.Wang D, Ge B, Li L, Shan J, Ding Y. J Org Chem. 2014;79:8607. doi: 10.1021/jo501467v.Wang D, Yu X, Zhao K, Li L, Ding Y. Tetrahedron Lett. 2014;55:5739.Yang Y, Wu X, Han J, Mao S, Qian X, Wang L. Eur J Org Chem. 2014:6854.Chan L, McNally A, Toh QY, Mendoza A, Gaunt MJ. Chem Sci. 2015;6:1277. doi: 10.1039/c4sc02856b.Riedmueller S, Nachtsheim BJ. Synlett. 2015;26:651.Sundalam SK, Stuart DR. J Org Chem. 2015;80:6456. doi: 10.1021/acs.joc.5b00907.Tinnis F, Stridfeldt E, Lundberg H, Adolfsson H, Olofsson B. Org Lett. 2015;17:2688. doi: 10.1021/acs.orglett.5b01079.Mao S, Geng X, Yang Y, Qian X, Wu S, Hanb J, Wang L. RSC Adv. 2015;5:36390.
  • 6.(a) For reviews of radiochemistry with diaryliodonium salt, see: Yusubov MS, Yu Svitich D, Larkina MS, Zhdankin VV. ARKIVOC. 2013;(i):364.Kovac M, Mavel S, Anderluh M. Curr Org Chem. 2013;17:2921.Cai L, Lu S, Pike VW. Eur J Org Chem. 2008:2853.
  • 7.a) Ichiishi N, Brooks AF, Topczewski JJ, Rodnick ME, Sanford MS, Scott PJH. Org Lett. 2014;16:3224. doi: 10.1021/ol501243g. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Ichiishi N, Canty AJ, Yates BF, Sanford MS. Organometallics. 2014;33:5525. doi: 10.1021/om5007903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.a) Pike VW, Aigbirhio FI. J Chem Soc Chem Commun. 1995:2215. [Google Scholar]; b) Shah A, Pike VW, Widdowson DA. J Chem Soc Perkin Trans. 1998;1:2043. [Google Scholar]; c) Chun J–H, Pike VW. Eur J Org Chem. 2012:4541. doi: 10.1002/ejoc.201200695. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Chun JH, Pike VW. Chem Commun. 2012;48:9921. doi: 10.1039/c2cc35005j. [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Chun J-H, Pike VW. Org Biomol Chem. 2013;11:6300. doi: 10.1039/c3ob41353e. [DOI] [PMC free article] [PubMed] [Google Scholar]; f) J.-H. Chun, S. Lu,; V. W. Pike, Eur. J. Org. Chem. 2011, 4439; g) Chun J-H, Lu S, Lee Y-S, Pike VW. J Org Chem. 2010;75:3332. doi: 10.1021/jo100361d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.a) Ross TL, Ermert J, Hocke C, Coenen HH. J Am Chem Soc. 2007;129:8018. doi: 10.1021/ja066850h. [DOI] [PubMed] [Google Scholar]; b) Helfer A, Meleán JC, Ermert J, Infantino A, Coenen HH. Appl Radiat Isot. 2013;82:264. doi: 10.1016/j.apradiso.2013.08.011. [DOI] [PubMed] [Google Scholar]; c) Ross TL, Ermert J, Coenen HH. Molecules. 2011;16:7621. doi: 10.3390/molecules16097621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.a) Kuik W, Kema IP, Brouwers Adrienne H, Zijlma R, Neumann KD, Dierckx RAJO, DiMagno SG, Elsinga PH. J Nucl Med. 2015;56:106. doi: 10.2967/jnumed.114.145730. [DOI] [PubMed] [Google Scholar]; b) Neumann KD, Qin L, Vavere AL, Snyder SE, DiMagno SG. J Nucl Med. 2012;53:21P. [Google Scholar]; c) Neumann K, Glaspy K, Vavere A, Snyder SE, DiMagno SG. J Nucl Med. 2013;54:223P. [Google Scholar]; d) Neumann KD, Vavere AL, Snyder SE, DiMagno SG. J Labelled Compd Radiopharm. 2011;54:S492. [Google Scholar]
  • 11.a) Moon BS, Kil HS, Park JH, Kim JS, Park J, Chi DY, Lee BC, Kim SE. Org Biomol Chem. 2011;9:8346. doi: 10.1039/c1ob06277h. [DOI] [PubMed] [Google Scholar]; b) Chun J, Telu S, Lu S, Pike VW. Org Biomol Chem. 2013;11:5094. doi: 10.1039/c3ob40742j. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) R. Edwards, A. D. Westwell, S. Daniels, T. Wirth, Eur. J. Org. Chem. 2015, 625; d) Zlatopolskiy BD, Zischler J, Krapf P, Zarrad F, Urusova EA, Kordys E, Endepols H, Neumaier B. Chem Eur J. 2015;21:5972. doi: 10.1002/chem.201405586. [DOI] [PubMed] [Google Scholar]; e) Jang KS, Jung Y-W, Gu G, Koeppe RA, Sherman PS, Quesada CA, Raffel DM. J Med Chem. 2013;56:7312. doi: 10.1021/jm400770g. [DOI] [PMC free article] [PubMed] [Google Scholar]; f) Carroll MA, Nairne J, Woodcraft JL. J Labelled Compd Radiopharm. 2007;50:452. [Google Scholar]
  • 12.a) Shah A, Pike VW, Widdowson DA. J Chem Soc, Perkin Trans. 1997;1:2463. [Google Scholar]; b) Kitamura T, Matsuyuki J, Taniguchi H. Synthesis. 1994:147. [Google Scholar]; c) Kitamura T, Matsuyuki J, Nagata K, Furuki R, Taniguchi H. Synthesis. 1992:945. [Google Scholar]; d) Carroll MA, Pike VW, Widdowson DA. Tetrahedron Lett. 2000;41:5393. [Google Scholar]; e) Zhdankin VV, Scheuller MC, Stang PJ. Tetrahedron Lett. 1993;34:6853. [Google Scholar]; f) Stang PJ, Zhdankin VV, Tykwinski R. Tetrahedron Lett. 1992;33:1419. [Google Scholar]; g) Pike VW, Butt F, Shah A, Widdowson DA. J Chem Soc, Perkin Trans. 1999;1:245. [Google Scholar]; h) G. F. Koser, R. H. Wettach, C. S. Smith, J. Org. Chem. 1980, 45, 1543; i) Stang PJ, Zhdankin VV, Tykwinski R, Zefirov NS. Tetrahedron Lett. 1991;32:7497. [Google Scholar]; j) Ochiai M, Toyonari M, Nagaoka T, Chen DW, Kida M. Tetrahedron Lett. 1997;38:6709. [Google Scholar]; k) Kitamura T, Kotani M, Fujiwara Y. Tetrahedron Lett. 1996;37:3721. [Google Scholar]
  • 13.a) Iwama T, Birman VB, Kozmin SA, Rawal VH. Org Lett. 1999;1:673. doi: 10.1021/ol990759j. [DOI] [PubMed] [Google Scholar]; b) Hossain MD, Kitamura T. Tetrahedron. 2006;62:6955. [Google Scholar]; c) Hossain MD, Kitamura T. J Org Chem. 2006;71:9903. doi: 10.1021/jo061889q. [DOI] [PubMed] [Google Scholar]; d) A. Kryska, L. Skulski, Molecules 2001, 6, 875; e) P. Kazmierczak, L. Skulski, Synthesis 1995, 1027; f) M. Bielawski, B. Olofsson, Chem. Commun. 2007, 2521; g) M. Bielawski, M. Zhu, B. Olofsson, Adv. Synth. Catal. 2007, 349, 2610; h) Bielawski M, Aili D, Olofsson B. J Org Chem. 2008;73:4602. doi: 10.1021/jo8004974. [DOI] [PubMed] [Google Scholar]; i) Zhu M, Jalalian N, Olofsson B. Synlett. 2008:592. [Google Scholar]; j) Merritt EA, Malmgren J, Klinke FJ, Olofsson B. Synlett. 2009:2277. [Google Scholar]
  • 14.Ye C, Twamley B, Shreeve JM. Org Lett. 2005;7:3961. doi: 10.1021/ol051446t. [DOI] [PubMed] [Google Scholar]
  • 15.Dohi T, Maruyama A, Takenaga N, Senami K, Minamitsuji Y, Fujioka H, Caemmerer SB, Kita Y. Angew Chem Int Ed. 2008;47:3787. doi: 10.1002/anie.200800464. [DOI] [PubMed] [Google Scholar]
  • 16.a) Uyanik M, Yasui T, Ishihara K. Tetrahedron. 2010;66:5841. [Google Scholar]; b) Uyanik M, Yasui T, Ishihara K. Angew Chem Int Ed. 2010;49:2175. doi: 10.1002/anie.200907352. [DOI] [PubMed] [Google Scholar]; c) Uyanik M, Yasui T, Ishihara K. Angew Chem Int Ed. 2013;52:9215. doi: 10.1002/anie.201303559. [DOI] [PubMed] [Google Scholar]
  • 17.Christe KO, Dixon DA, McLemore D, Wilson WW, Sheehy JA, Boatz JA. J Fluorine Chem. 2000;101:151. [Google Scholar]
  • 18.Hu B, Miller WH, Neumann KD, Linstad EJ, DiMagno SG. Chem Eur J. 2015;21:6394. doi: 10.1002/chem.201500151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ground Fluor Pharmaceuticals, Inc. Lincoln, NE.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

supporting information

RESOURCES